Global Cell and Gene Therapy in Ophthalmology Research Report 2024: Market Anticipated to Soar with Projected CAGR Growth of 50.8% by 2029 [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Despite the high cost of therapies, linked to the intensive research and development and narrow patient populations, the CGT market in ophthalmology is projected to expand from $46 million in 2023 to an impressive $3.0 billion in 2029. The dynamic field of ophthalmology is witnessing a transformative phase with the advent of cell and gene therapies (CGTs). The existing market, primarily driven by a handful of therapies such as Luxturna for retinitis pigmentosa and Leber congenital amaurosis, is expected to experience significant growth. Rare and severe ophthalmic diseases, previously lacking effective treatment options, are at the forefront of this surge. Regulatory and Clinical Developments The evolution of the CGT segment is underpinned by comprehensive guidelines across major markets, providing a framework for Chemistry, Manufacturing, and Controls (CMC), preclinical assessments, and clinical trials. With the FDA offering specific guidance for gene therapy applications in re
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Waters And Johns Solidify Stakes As Pickleball Number Ones At PPA Atlanta Slam [Forbes]Forbes
- United States Platelet Rich Plasma Industry Research 2024-2032: Increasing Healthcare Expenditures Fuel Growth of PRP-Based Procedures, Non-Invasive Medical Procedures Drive PRP Therapy Demand [Yahoo! Finance]Yahoo! Finance
- Ethereum price today: ETH is down 1.01% today [USA TODAY]USA TODAY
- Global Surgical Equipment Market is Anticipated to Hit USD 32.96 Billion, With a CAGR of 8.8% CAGR by 2032 - Report by Polaris Market Research (PMR) [Yahoo! Finance]Yahoo! Finance
- TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 5/20/24 - Form 25-NSE
- 5/17/24 - Form 8-K
- 5/16/24 - Form 424B2
- JNJ's page on the SEC website